The quarter came in modestly worse than expected. Net loss was $69.8 million, or $0.72 per share, versus published expectations clustered around a $0.66–$0.68 loss. The miss is small, but there was no revenue contribution to offset the launch transition.
| Metric | Q1 FY2026 | Q1 FY2025 / prior period | Expectation or change |
|---|---|---|---|
| R&D expense | $49.3M | $57.8M | Down $8.6M year over year |
| SG&A expense | $19.0M | $32.6M | Down $13.6M year over year |
| Net loss | $69.8M | $86.7M | Narrower reported loss |
| Diluted EPS | $(0.72) | $(0.95) | Published consensus around $(0.66)–$(0.68) |
| Cash, equivalents and short-term investments | $195.3M | — | Down from $268.9M at March 31, 2026 |
The main strategic news was already public before this filing. FDA approval of TUDRIQEV was announced on August 6, 2026, and the company had also recently completed a $150 million financing; this release mainly confirms the commercial transition rather than creating a fresh regulatory surprise. 〔0〕
The balance sheet is now positioned for launch, but dilution and spending are the trade-off. Management says the $141.0 million of net August financing proceeds, combined with existing liquidity, should fund operations for more than twelve months, including commercial scale-up and the IGNYTE-3 confirmatory trial.
The incremental operating signal is preparation, not proof of commercial execution. A new Chief Commercial Officer joins August 18, and product is expected in the U.S. market within 60 days, but the filing provides no early demand, reimbursement, or launch-revenue evidence yet. 〔1〕
Net read: a narrow earnings miss against a largely anticipated launch milestone. The approval and financing improve the company’s runway and readiness, but because both were already disclosed, the fresh quarterly result is principally a slightly larger-than-expected loss while investors wait for launch execution and confirmatory-trial validation.
Read the original 8-K on SEC EDGAR ↗